You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) - design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis
|
|---|---|
| Published in |
BMC Infectious Diseases, October 2014
|
| DOI | 10.1186/s12879-014-0543-y |
| Pubmed ID | |
| Authors |
Anneleen Berende, Hadewych JM ter Hofstede, A Rogier T Donders, Henriët van Middendorp, Roy PC Kessels, Eddy MM Adang, Fidel J Vos, Andrea WM Evers, Bart Jan Kullberg |
| Abstract |
BackgroundLyme borreliosis, a potentially severe tick-borne infection caused by Borrelia burgdorferi, can cause multi-system inflammatory disease. The incidence has been increasing, as has the number of patients with persistent symptoms attributed to Borrelia. These symptoms, also referred to as post-Lyme disease syndrome, may follow an erythema migrans or other Lyme manifestations, and include pain, fatigue, and cognitive disturbances. The optimal duration of treatment for these symptoms is a subject of controversy. The PLEASE study is designed to determine whether prolonged antibiotic treatment leads to better patient outcome than standard treatment.Methods/DesignThe PLEASE study is a double-blind, randomized, placebo-controlled trial. Based on power analysis and compensating for possible loss to follow-up, a minimum of 255 patients with borreliosis-attributed persistent symptoms are included. These symptoms are either (a) temporally related to an erythema migrans or otherwise proven symptomatic borreliosis, or (b) accompanied by a positive B. burgdorferi IgG or IgM immunoblot. All patients receive open-label ceftriaxone for two weeks. Patients are then randomized (ratio 1:1:1) to blinded oral follow-up treatment for 12 weeks with (I) doxycycline, (II) clarithromycin combined with hydroxychloroquine, or (III) placebo. The primary outcome is the physical component summary score (PCS) of the RAND-36 Health Status Inventory (RAND SF-36) at week 14. Secondary outcomes include physical and mental aspects of health-related quality of life (assessed by the subscales of the RAND SF-36), fatigue, neuropsychological evaluation, physical activity, and cost-effectiveness.DiscussionThis article describes the background and design issues of the PLEASE study protocol. The results of this study may provide evidence for prescribing or withholding prolonged antibiotic treatment.Trial registrationClinicalTrials.gov: NCT01207739, Netherlands Trial Register: NTR2469. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 22% |
| Netherlands | 2 | 11% |
| Unknown | 12 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 78% |
| Practitioners (doctors, other healthcare professionals) | 3 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 2% |
| Netherlands | 1 | <1% |
| Sweden | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 118 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 15% |
| Student > Master | 19 | 15% |
| Student > Bachelor | 14 | 11% |
| Student > Ph. D. Student | 10 | 8% |
| Professor | 6 | 5% |
| Other | 20 | 16% |
| Unknown | 36 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 25% |
| Nursing and Health Professions | 9 | 7% |
| Psychology | 7 | 6% |
| Agricultural and Biological Sciences | 7 | 6% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Other | 24 | 19% |
| Unknown | 40 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 March 2016.
All research outputs
#2,070,968
of 24,629,540 outputs
Outputs from BMC Infectious Diseases
#569
of 8,246 outputs
Outputs of similar age
#23,219
of 260,970 outputs
Outputs of similar age from BMC Infectious Diseases
#9
of 180 outputs
Altmetric has tracked 24,629,540 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,246 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 260,970 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.